Revolutionizing Cardiac Monitoring
In a significant leap for medical diagnostic technology, a new, lightweight, and wireless heart monitor has officially entered clinical trials. Developed through intensive research at RMIT University and now being commercialized by the startup Lubdub, this gel-free ECG patch is designed to provide high-fidelity, medical-grade heart monitoring without the constraints of traditional, bulky hospital equipment. The device is currently being utilized by patients at Midlands Medical Specialists in Perth, Western Australia, marking a pivotal transition from laboratory prototype to real-world clinical application.
Traditional Holter monitors have long served as the standard for outpatient cardiac monitoring, yet they are often cumbersome and require conductive gels that can irritate the skin. The Lubdub patch addresses these challenges by utilizing advanced, flexible sensor technology that maintains consistent contact with the skin. Early testing on volunteers has yielded remarkable results, with data clarity reported to be 18 times higher than that of traditional monitors. This cleaner signal not only enhances diagnostic accuracy but also significantly reduces the time healthcare professionals spend filtering noise from cardiac reports, potentially allowing clinics to manage an 85% higher patient volume.
Why It Matters
- Enhanced Accessibility: By moving monitoring from the hospital to the daily environment, the patch helps bridge the gap between the onset of symptoms and critical diagnosis, particularly for patients in remote or underserved regions.
- Streamlined Diagnostics: The system aims to simplify the current fragmented approach to heart health, which often requires multiple, separate appointments for ECGs, blood work, and echocardiograms.
- Operational Efficiency: The high-quality data output reduces manual reporting workload, optimizing clinic resources and improving patient throughput.
A Vision for Comprehensive Heart Health
The ECG patch is just the first component of an ambitious, three-pronged diagnostic platform being developed by Lubdub. Looking ahead, the company intends to integrate this wearable technology with non-invasive biomarker testing and wearable ultrasound imaging. By unifying these disparate diagnostic tools into a single, cohesive software platform, Lubdub hopes to provide clinicians with a holistic view of a patient’s heart health in real-time, effectively moving toward a model where prevention and early detection are prioritized over emergency-room interventions.
The motivation behind this technology is deeply rooted in personal experience and the global urgency of cardiovascular disease. With heart failure being a primary cause of global mortality—and many patients suffering from symptoms for years before receiving an official diagnosis—the necessity for more accessible, effective screening tools has never been greater. Lubdub’s innovation, which has been recognized by the Heart Foundation as one of the top ten most promising heart health projects of 2026, represents a transformative step in making cardiac care more proactive and patient-centric.
Outlook and Implications
As the clinical trial in Western Australia progresses, the gathered data will be fundamental for securing regulatory approval and refining the manufacturing process. Through the ongoing support of RMIT University and access to specialized pilot manufacturing facilities, Lubdub is effectively translating cutting-edge electronics into a practical, life-saving product. If successful, this technology could fundamentally alter the landscape of cardiology, enabling doctors to monitor heart conditions with unprecedented precision, convenience, and reach, ultimately saving lives through earlier detection and intervention.









